Best TRT Clinics 2026: Ranked Cash-Pay Testosterone Telehealth

Testosterone replacement therapy (TRT) is a legitimate medical treatment for men with clinically diagnosed hypogonadism. It is also one of the most aggressively marketed categories in DTC telehealth, where the line between “low T symptom relief” and overprescribing blurs constantly. This page ranks the TRT-focused telehealth clinics that meet a minimum evidentiary bar: a real diagnostic workup against the Endocrine Society 2018 threshold (morning total testosterone below 300 ng/dL on two separate occasions, plus consistent symptoms; Bhasin et al., J Clin Endocrinol Metab^[2]), ongoing lab monitoring including hematocrit and PSA, multiple delivery modalities, and transparent pricing. We do not rank pellet-mill operators that prescribe T on the first call without baseline labs, and we do not rank clinics that refuse to disclose monitoring cadence. TRT is also contextualized here against the TRAVERSE cardiovascular safety trial (Lincoff et al., NEJM 2023, n=5,246 hypogonadal men with cardiovascular disease or risk^[1]), which established non-inferiority for major adverse cardiac events versus placebo at 22-month follow-up but did flag higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Here is the verified ranking.

How we rank TRT clinics

TRT is a YMYL (your-money-or-your-life) medical category. A bad provider can produce real harm: prescribing T to a man with untreated prostate cancer, missing erythrocytosis (hematocrit above 54%), failing to monitor for atrial fibrillation, or suppressing fertility in a man who still wants children. A good provider should look more like an endocrinology practice than a supplement company. Our ranking weights five criteria, in this order:

1. Diagnostic rigor. Does the clinic require two morning total testosterone measurements below 300 ng/dL plus symptom assessment before prescribing, per the Endocrine Society 2018 guideline^[2]? Does the intake include free T, SHBG, LH, FSH, prolactin, estradiol, PSA (for men 40+ or with risk factors), CBC for baseline hematocrit, and a comprehensive metabolic panel? Clinics that prescribe T on a symptom questionnaire alone, or on a single random testosterone draw, are excluded.
2. Formulary breadth. Does the clinic offer multiple delivery modalities — injectable cypionate or enanthate, transdermal gel (1% or 1.62%), nasal gel (Natesto), pellet, oral undecanoate (Jatenzo / Kyzatrex / Tlando) — or only one? Patients with different lifestyles, fertility plans, and side-effect profiles need different modalities. Injection-only clinics are not disqualified but they score lower.
3. Monitoring rigor. Does the clinic re-check labs at 3 months and 6 months and then annually? Does the panel include total and free T, hematocrit, PSA, estradiol, and a metabolic panel? Does the clinic adjust dose when hematocrit exceeds 50%, hold therapy at 54%, and order a urology consult when PSA rises greater than 1.4 ng/mL in one year or greater than 0.4 ng/mL per year sustained?
4. Pricing transparency. Are monthly costs (medication + labs + clinical visits) disclosed publicly before account creation? Is the labs bundle clearly itemized? Hidden labs fees and visit-charge bait-and-switch are common patterns in this category.
5. State coverage. Are all 50 states served, or is the clinic regional? Are HCG and anastrozole (often stacked with T) prescribed where state law permits?

Below the ranking we also discuss modality trade-offs, the TRAVERSE cardiovascular context, lab monitoring expectations, insurance reality (most TRT in DTC telehealth is cash-pay), the emerging TRT + GLP-1 stacking trend, and when not to TRT.

The diagnostic threshold: when TRT is actually appropriate

The Endocrine Society 2018 clinical practice guideline (Bhasin et al., J Clin Endocrinol Metab^[2]) is the canonical reference. The guideline recommends:

• A diagnosis of hypogonadism is appropriate when both (a) the patient has consistent symptoms and signs (reduced libido, decreased spontaneous erections, decreased energy, depressed mood, loss of body hair, hot flushes, decreased lean mass and muscle strength, increased body fat, decreased bone mineral density) and (b) total testosterone is unequivocally and consistently low on at least two separate morning fasting measurements taken on different days.
• The conventional threshold used in the guideline and in the TRAVERSE inclusion criteria is total testosterone below 300 ng/dL (~10.4 nmol/L). Reference ranges vary by assay; if total T is borderline (250–400 ng/dL), the workup should include calculated or measured free testosterone plus SHBG.
• Morning timing matters because total T peaks 7–10 AM and falls 20–25% by afternoon. A single afternoon draw is not diagnostic.
• A complete workup also includes LH and FSH (to distinguish primary vs secondary hypogonadism), prolactin (to rule out prolactinoma), and an evaluation for reversible causes (sleep apnea, obesity, opioid use, glucocorticoid use, alcohol excess, hypothyroidism).

Any DTC TRT clinic that prescribes testosterone without checking these boxes is, by the Endocrine Society standard, prescribing outside the guideline. Patients reading this page should understand that “low T symptoms” (fatigue, low libido, weight gain) overlap with sleep apnea, depression, untreated hypothyroidism, and uncontrolled type 2 diabetes — all of which need treatment in their own right and several of which improve testosterone when treated.

The 2026 ranking: best TRT clinics

Ranked on the five criteria above. Pricing and state coverage are as of 2026-05-28 and can change; verify on the clinic site before purchase.

1. Hone Health — best overall for established cash-pay TRT

Why it ranks here. Hone Health (our provider page) is the longest-running cash-pay TRT telehealth brand we cover, with a hormone-focused intake that runs at-home phlebotomy through a national lab network, a baseline panel that includes total and free T, SHBG, LH, FSH, estradiol, PSA, CBC (hematocrit), and a full metabolic panel, and a named medical group performing the clinical work. The platform offers injectable cypionate as the default, with transdermal gel for patients who prefer no injections, and includes anastrozole and HCG where clinically indicated. Membership is required ($25/mo Basic; $149/mo Premium); medications and labs are separate. Hone's weight- loss formulary (compounded liraglutide, naltrexone, bupropion, phentermine, topiramate) sits alongside the hormone program, which is relevant for the TRT + GLP-1 stacking question discussed below. Honest caveats: pricing is not displayed up-front (gated behind the intake), and the membership-plus-medication structure means total monthly cost depends on which add-ons you select. Trustpilot reviews are mixed on customer support response times.

2. Marek Health — best for premium / concierge clients

Why it ranks here. Marek Health is a higher-end hormone-optimization service that runs an unusually thorough baseline panel (often 40+ markers including DHEA-S, IGF-1, full thyroid, lipid subfractions, inflammatory markers, micronutrients) and assigns a dedicated health coach in addition to the prescribing clinician. The clinical model leans into individualized protocols including HCG for fertility preservation, low-dose anastrozole where estradiol management is needed, and adjunctive peptides where state law permits. Pricing is premium — labs and consults run several hundred dollars before medication — and that is the trade-off. This is not a $99/month bargain TRT clinic; it is a hormone-optimization service for patients who want extensive baseline data and tighter touchpoints. Honest caveats: the broader hormone-optimization positioning attracts patients seeking off-label or wellness-driven T (men with mid-range baseline T who want supraphysiologic levels), and prospective patients should be candid with the clinical team about goals; the prescriber will refuse to prescribe outside guideline territory, but the marketing language sometimes suggests otherwise.

3. Maximus — best DTC men's-health platform with TRT

Why it ranks here. Maximus (our provider page) is a 50-state men's-health DTC platform whose core product is testosterone optimization — both classical injectable TRT and enclomiphene-based protocols for men who want to raise endogenous T without exogenous testosterone (useful for patients prioritizing fertility). Compounded GLP-1 is also available (compounded semaglutide from around $99/month, tirzepatide also offered), which makes Maximus a natural pick for the TRT + GLP-1 stacking pattern. Honest caveats: this is a men's-health marketing platform first, a clinical TRT service second — the messaging is heavy on testosterone-as-vitality framing. Innerbody's review of Maximus cites a BBB F-rating and complaints about unfulfilled prescriptions, which is a real operational signal. Pricing is not consistently displayed up-front on the public site (most product pages are JavaScript-rendered). We rank Maximus here because the formulary breadth, state coverage, and TRT + GLP-1 + enclomiphene combination is genuinely useful when it works; the operational concerns are why it sits at #3 rather than #1.

4. Male Excel — best for multi-condition men's health (TRT + ED + thyroid)

Why it ranks here. Male Excel is a men's- health-focused telehealth clinic offering TRT alongside ED treatment, thyroid optimization, weight loss (compounded GLP-1), and broader hormone work. The clinical model is multi-modality: injectable testosterone cypionate is the default, with transdermal cream as an option, and HCG plus anastrozole are routinely included where clinically warranted. The intake includes a full baseline lab panel. The appeal is one platform for a man with multiple overlapping issues (low T plus ED, low T plus subclinical hypothyroidism, low T plus weight) rather than three separate logins. Pricing is moderate (membership plus medication plus labs). Honest caveats: combining multiple endocrine therapies in one provider is convenient but also concentrates prescribing decisions in clinicians whose primary specialty is not necessarily endocrinology — patients with complex thyroid disease or suspected pituitary pathology should still see a board-certified endocrinologist. The website's marketing leans on before-and-after testimonials, which are not evidence.

5. Brightmeds — best multi-product general-purpose option

Why it ranks here. Brightmeds is a broader DTC platform with TRT as one of several offerings (alongside GLP-1 weight loss, sexual health, and other categories). The TRT program covers injectable testosterone cypionate and transdermal gel, with the standard baseline labs and a 3-month follow-up protocol. Pricing is moderate and transparent. This is a reasonable general-purpose option for a patient who wants TRT from a brand that is not exclusively a men's-health vertical. Honest caveats: Brightmeds is not specialized in hormone optimization the way Hone or Marek are. The intake is competent but lighter than the top-ranked options. Patients with edge cases (secondary hypogonadism, fertility goals, complex estradiol management) will be better served by a hormone-specialized clinic.

6. Feel30 — best concierge-style TRT for newer patients

Why it ranks here. Feel30 is a newer concierge-style TRT service that emphasizes 1-on-1 clinician access and individualized dose titration. The clinical model looks reasonable: baseline labs include the canonical hormone and PSA panel, follow-up labs at 3 and 6 months, and an injectable testosterone protocol with optional anastrozole and HCG. Pricing is mid-range. Honest caveats: as a newer entrant, the long-term operational track record is shorter than Hone or Marek; the named-clinician transparency on the public site has been improving but is not yet at the level of the top-ranked clinics. Worth considering if you value the high-touch concierge feel and the pricing aligns.

7. Taurus Meds — best for patients seeking a Katalys-partner DTC option

Why it ranks here. Taurus Meds is a Katalys- affiliated DTC men's-health platform offering TRT alongside compounded GLP-1 and other men's wellness categories. Pricing is competitive. The platform serves the lower-friction end of the TRT market: standardized protocols, fast intake, injectable T as the primary modality. We rank Taurus Meds at #7 because the clinical depth (intake breadth, named clinical team on the public site, monitoring cadence transparency) is lighter than the higher-ranked clinics. For a patient who already has a recent low-T workup from a primary-care doctor and wants a reasonably priced cash-pay maintenance provider, this is a defensible option; for an initial diagnostic workup, the higher-ranked clinics are better suited.

Modality comparison: how testosterone is delivered

TRT comes in five FDA-approved delivery routes plus a less common one. Each has different pharmacokinetics, side-effect profiles, and lifestyle fit. The Endocrine Society 2018 guideline^[2] notes that choice of formulation should be individualized to patient preference, cost, and tolerance.

• Injectable testosterone cypionate or enanthate (intramuscular or subcutaneous, weekly or twice-weekly): The default in most US TRT practice. Cypionate has a half-life of ~8 days; weekly or twice-weekly dosing produces relatively stable serum levels. Cost is the lowest of any modality (~$25–75/month of medication at typical cash prices). Disadvantages: peak-to-trough variability if dosed less frequently than weekly, injection-site reactions, and the patient must self-inject. The TRAVERSE trial used transdermal gel rather than injection^[1], so the cardiovascular safety data is technically gel-specific, though class effects are generally assumed.
• Transdermal gel (1% or 1.62%, daily): Applied to the shoulders, upper arms, or abdomen once daily. Produces stable serum levels without peak-trough swings. Disadvantage: transfer risk — the gel can transfer to a partner, child, or pet through skin contact for several hours after application. Daily compliance is essential; missed doses drop levels quickly. Costs run $200–500/month at cash-pay prices for brand AndroGel or Testim; generic gel is cheaper.
• Pellet implants (Testopel, every 3–6 months): Subcutaneous pellets implanted in the hip via a small in-office procedure. Provides 3–6 months of steady-state testosterone with no daily or weekly action required. Once implanted, however, the dose cannot be reduced — if hematocrit rises or PSA rises or the patient develops a contraindication, the only options are to wait it out, draw blood (phlebotomy), or surgically remove the pellets. We consider pellets a lower-tier choice for new TRT patients because of this dose-reversibility problem; they are more defensible for stable long-term patients with a known well-tolerated dose.
• Nasal gel (Natesto, 3x daily): Applied intranasally three times per day. The shortest half-life of any FDA-approved T product, which is the basis of its key advantage: preserves fertility in many men, because the short-duration daily peak does not fully suppress the hypothalamic-pituitary-gonadal axis the way long-acting injection or gel does. Disadvantages: three-times-daily dosing is a real adherence burden, nasal irritation is common, and serum levels are more variable than with gel or injection. The fertility-preservation niche is the main reason it shows up in TRT formularies.
• Oral testosterone undecanoate (Jatenzo, Kyzatrex, Tlando, twice daily with food): A newer FDA-approved oral route that bypasses the hepatotoxicity problems of older oral T preparations. Requires twice-daily dosing with a fat-containing meal for absorption. Cost is high (typically $500–1,000+/month cash). Useful for the small subset of patients with strong needle aversion plus gel-transfer concerns, but not commonly chosen because of cost.
• Buccal patch (Striant): Twice-daily patch applied to the gum line. Rarely prescribed because of mucosal irritation and adherence problems. Most TRT clinics do not carry it.

Most DTC TRT clinics default to injectable cypionate (cheapest, most stable, simplest). The clinics with deeper formularies (Hone, Marek, Male Excel) also offer gel; only a handful offer nasal Natesto and very few offer pellets.

The TRAVERSE trial: cardiovascular safety context

TRAVERSE (Lincoff et al., NEJM 2023, PMID 37326322^[1]) is the landmark cardiovascular safety trial that FDA required after multiple observational studies in the 2010s suggested an MI signal in older TRT patients. The design:

• 5,246 hypogonadal men aged 45–80 with screening total testosterone less than 300 ng/dL on two measurements, plus established cardiovascular disease or high cardiovascular risk.
• Intervention: transdermal testosterone gel (1.62%) titrated to maintain serum T at 350–750 ng/dL, vs placebo gel.
• Mean follow-up: 22 months.
• Primary endpoint (composite MACE: CV death, non-fatal MI, non-fatal stroke): hazard ratio 0.96 (95% CI 0.78–1.17), establishing non-inferiority of TRT vs placebo for major adverse cardiac events.

That is the headline. The trial also flagged statistically higher rates in the TRT arm of three secondary endpoints: atrial fibrillation, acute kidney injury, and pulmonary embolism. The absolute differences were small but real. The Endocrine Society and the FDA label updates following TRAVERSE both reflect the same practical takeaway: TRT does not increase major cardiac events in the indicated population (hypogonadal men with cardiovascular risk), but prescribers should counsel patients about the AFib, AKI, and PE signals, and patients with prior unprovoked VTE or AFib warrant additional caution. TRAVERSE does not license prescribing T to eugonadal men for “optimization,” and it does not generalize to supraphysiologic dosing.

Lab monitoring: what a competent TRT program tracks

A defensible TRT program runs lab work at baseline, at 3 months, at 6 months, and then at least annually. Per the Endocrine Society 2018 guideline^[2] and standard urology practice, the panel should include:

• Total and free testosterone — goal is mid-normal range (typically 400–700 ng/dL trough on injectable; assay-dependent). Levels above the upper end of the normal range invite dose reduction.
• Hematocrit (via CBC) — the single most important safety monitor. TRT increases red blood cell mass via erythropoietin stimulation. Hematocrit greater than 50% warrants dose reduction; greater than 54% generally warrants holding TRT until hematocrit normalizes (sometimes via therapeutic phlebotomy). Untreated erythrocytosis raises thrombotic risk.
• PSA (prostate-specific antigen) for men 40+ or with risk factors — baseline before initiation, then at 3 months and 12 months. A rise greater than 1.4 ng/mL in one year, or sustained rise greater than 0.4 ng/mL per year, warrants urology consultation. TRT does not cause prostate cancer (per current evidence) but can accelerate growth of an undiagnosed cancer, so screening matters.
• Estradiol — testosterone aromatizes to estradiol; some men develop gynecomastia or water retention at higher T doses. Low-dose anastrozole is sometimes added when estradiol is high and symptomatic, but routine anastrozole for normal estradiol is overprescribing.
• LH and FSH at baseline (and at follow-up if fertility is a concern).
• Comprehensive metabolic panel and lipid panel at baseline and annually.

Clinics that do labs only at baseline and then never again, or clinics that do not include hematocrit or PSA in the standard monitoring panel, fail this criterion. Several DTC TRT brands we have audited do not publicly disclose their monitoring cadence at all — that opacity is itself a yellow flag.

Insurance landscape: most TRT is cash-pay in DTC telehealth

Commercial insurance and Medicare will cover testosterone replacement therapy when the diagnosis of hypogonadism is confirmed (typically requiring documented low total T below 300 ng/dL on two morning draws, plus consistent symptoms, plus appropriate ICD-10 coding such as E29.1 for testicular hypofunction or E23.0 for hypopituitarism). The traditional path is through a urologist or endocrinologist, with brand-name AndroGel, Testim, or generic injectable cypionate dispensed through a retail pharmacy and processed through pharmacy benefits.

DTC TRT telehealth, however, is almost entirely cash-pay. The clinics ranked above generally do not bill commercial insurance. Several reasons: rapid intake without a documented multi-month symptom workup does not satisfy most payer prior-authorization criteria; compounded testosterone (used by some DTC platforms) is rarely covered; the DTC pricing model relies on a recurring cash subscription that is harder to operationalize through third-party billing. If you have insurance that covers TRT and a primary-care doctor or urologist who is comfortable prescribing, that path is typically cheaper than DTC cash-pay. DTC is the right choice if you do not have a covered prescriber, if you have already been worked up and just need maintenance prescribing, or if you value the convenience of the telehealth model over the cost difference.

The TRT + GLP-1 stacking trend

A growing fraction of TRT patients are also on GLP-1 receptor agonists for weight loss (compounded semaglutide, brand Wegovy, compounded tirzepatide, brand Zepbound, or oral orforglipron / Foundayo). Several of the clinics ranked above (Hone, Maximus, Male Excel, Brightmeds, Taurus Meds) explicitly offer both. The rationale and the caveats:

• Obesity lowers testosterone. Adipose tissue aromatizes testosterone to estradiol, and obesity-associated insulin resistance and inflammation suppress the HPG axis. Many men with mid-range low T (250–350 ng/dL) and significant excess weight will see total T normalize after 15–20% weight loss alone — without TRT. For these men, GLP-1 first is the better-evidenced first step.
• GLP-1 magnitudes are large. STEP-1 (Wilding et al., NEJM 2021^[3]) reported −14.9% total body weight loss with semaglutide 2.4 mg at 68 weeks. SURMOUNT-1 (Jastreboff et al., NEJM 2022^[4]) reported −20.9% with tirzepatide 15 mg at 72 weeks.
• For men with frank hypogonadism (total T well below 250 ng/dL with clear symptoms), TRT plus GLP-1 is reasonable when both are indicated. The combination is well-tolerated in clinical practice but is not yet supported by a dedicated RCT.
• Resistance training and protein adequacy are the third leg of the stool — both TRT and GLP-1 users need to defend lean mass during weight loss. See our exercise pairing article and protein calculator.

When NOT to TRT

The Endocrine Society guideline^[2] lists absolute and relative contraindications. The most important ones for DTC patients to understand:

• Untreated, active prostate cancer. TRT is contraindicated. Men with treated prostate cancer can sometimes receive TRT under urology supervision, but this is not a DTC-appropriate decision.
• Untreated severe obstructive sleep apnea. TRT can worsen sleep apnea. Untreated severe OSA should be managed (CPAP or alternative) before initiating TRT.
• Active fertility plans. Exogenous testosterone suppresses the HPG axis and dramatically reduces sperm production within 3–6 months. Men actively trying to conceive should generally not start TRT. Alternatives include enclomiphene (a SERM that raises endogenous T while preserving fertility) or HCG. Discuss with the prescriber upfront.
• Uncontrolled heart failure. TRT can cause fluid retention; uncontrolled HF is a contraindication.
• Hematocrit above 50% at baseline. Treat the underlying erythrocytosis cause before initiating TRT, or plan for therapeutic phlebotomy as part of monitoring.
• Recent MI or stroke (within 6 months). Per Endocrine Society guidance, defer.
• History of unprovoked venous thromboembolism. TRAVERSE flagged a higher PE rate in the TRT arm^[1]; patients with prior unprovoked VTE warrant additional caution and shared decision-making.

Any DTC clinic that prescribes TRT without screening for these contraindications is operating outside the standard of care. The intake questionnaire should ask about prostate history, sleep apnea, fertility plans, cardiac history, and prior VTE.

Frequently asked questions

The FAQ schema below answers the highest-volume search queries on TRT clinic selection.

Bottom line

• TRT is a real medical therapy with a real diagnostic threshold: morning total T below 300 ng/dL on two measurements plus consistent symptoms (Endocrine Society 2018^[2]).
• TRAVERSE established cardiovascular non-inferiority for TRT in hypogonadal men with CV risk^[1], with secondary signals for AFib, AKI, and PE that patients should understand.
• The top-ranked DTC clinics for 2026 are Hone Health (best overall), Marek Health (best premium), and Maximus (best 50-state men's-health platform). Male Excel and Brightmeds are reasonable multi-product options. Feel30 is a defensible concierge entrant. Taurus Meds rounds out the list.
• Monitoring matters more than dosing strategy — hematocrit and PSA at baseline, 3 months, 6 months, and annually are non-negotiable.
• Most DTC TRT is cash-pay. Insurance covers TRT when hypogonadism is properly documented, but DTC clinics generally do not bill commercial insurance.
• For obese men with mid-range low T, GLP-1-driven weight loss first often normalizes testosterone without TRT^[3][4].
• Do not TRT with untreated prostate cancer, untreated severe OSA, active fertility plans, or recent VTE.

Related research and tools

• Best protein powder for weight loss on a GLP-1 — the lean-mass preservation side of the stacking conversation
• Exercise pairing on a GLP-1 — resistance training is the third leg of the TRT + GLP-1 + lifting stack
• GLP-1 protein calculator — daily protein target (1.6–2.0 g/kg) for lean-mass preservation
• Hone Health provider review — full pricing, formulary, and YMYL audit
• Maximus provider review — full pricing, state coverage, and operational notes
• What to eat on a GLP-1: the protein-first guide — the dietary side of body-composition optimization

Important disclaimer. This article is educational and does not constitute medical advice. Testosterone replacement therapy is a prescription medical treatment with material cardiovascular, hematologic, and prostate-cancer screening implications. Men considering TRT should be evaluated by a licensed clinician with a complete history, physical examination, and a full baseline laboratory workup that includes at least two morning total testosterone measurements, free testosterone (or SHBG), LH, FSH, PSA (for men 40+), CBC for baseline hematocrit, and a metabolic panel. The diagnostic threshold cited here (total T below 300 ng/dL on two morning measurements plus consistent symptoms) is the Endocrine Society 2018 guideline standard and may differ from individual clinical judgment in borderline cases. The TRAVERSE cardiovascular non-inferiority result applies to the studied population (hypogonadal men 45–80 with CV disease or risk) and should not be extrapolated to TRT prescribed to eugonadal men for wellness or performance reasons. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. Pricing and state coverage for each clinic reflect public disclosures available on the same date; verify before purchase. Weight Loss Rankings has affiliate relationships with several of the clinics listed, disclosed on each provider page; affiliate compensation does not influence the ranking order on this page, which is based on the five published criteria.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if material clinical evidence (TRAVERSE follow-up data, FDA label updates, Endocrine Society guideline revision) is published.